CompoAtlas

HELSURE

HELSURE, licence 80041185: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names
NUTRIDA
Licence holder
Nutrida Canada Corp.
NPN or DIN-HM
80041185
Status
Active licence
Licence date
21 March 2013
Revision date
Not provided
Form
Poudre
Route of administration
Orale
Application type
Officinale

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Isolat de protéine de soja

Source : Isolat de protéine de soja

Potency : 78.0 mg ÉAI Genistein

24.5 gNot calculated
Isolat de protéine de soja

Source : Isolat de protéine de soja

Potency : 9.375 mg ÉAI Genistin

Not specifiedNot calculated
Isolat de protéine de soja

Source : Isolat de protéine de soja

Potency : 87.375 mg ÉAI Isoflavones

Not specifiedNot calculated
Isolat de protéine de soja

Source : Glycine max - Graine

Potency : 78.0 mg ÉAI Genistein

24.5 gNot calculated
Isolat de protéine de soja

Source : Glycine max - Graine

Potency : 9.375 mg ÉAI Genistin

Not specifiedNot calculated
Isolat de protéine de soja

Source : Glycine max - Graine

Potency : 87.375 mg ÉAI Isoflavones

Not specifiedNot calculated

Non-medicinal ingredients

D-Fructose, Carbonate de calcium, Gomme de cellulose, Saveur de lait entier, Collagène hydrolysé

PopulationAgeQuantity per servingFrequency
Femmes ménopausées et en postménopauseNot specified30.0 g1.0 Tous les jours
Femmes en postménopauseNot specified30.0 g1.0 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D (Marini et al. 2007; Newton et al. 2006; Ye et al. 2006; Chen et al. 2004; Kreijkamp-Kaspers et al. 2004; Lydeking et al. 2004; Uesugi et al. 2003; Alekel et al. 2000; Potter et al. 1998). May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats) (D'Anna et al. 2007; Nahas et al. 2007; Williamson-Hughes et al. 2006; Crisafulli et al. 2004; Albert et al. 2002; Han et al. 2002; Scambia et al. 2000; Upmalis et al. 2000; Albertazzi et al. 1998).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80041185

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Enter to analyse, Shift+Enter for a new line